Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | terminated | Phase 1 | 142 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 21, 2022 | clinicaltrials |
| NCT02052193 | Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study | terminated | Phase 2 | 8 | University Hospital TuebingenOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02414750 | Vemurafenib Plus Cobimetinib in Metastatic Melanoma(REPOSIT) | terminated | Phase 2 | 78 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03464604 | Melanoma Accuracy Study; Phase 2 | terminated | — | 121 | Nova Scotia Health AuthorityOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT00945269 | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 3 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma(MASTERKEY-265) | terminated | Phase 3 | 713 | AmgenINDUSTRY | 21 | Nov 14, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT03445533 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | terminated | Phase 3 | 481 | Idera Pharmaceuticals, Inc.INDUSTRY | 11 | Nov 8, 2022 | clinicaltrials |
| NCT01810016 | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | terminated | Phase 1 | 8 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 12, 2022 | clinicaltrials |
| NCT01838200 | Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | terminated | Phase 1 | 5 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT00145158 | Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma | terminated | Phase 1 / Phase 2 | 23 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00145145 | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02601378 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | terminated | Phase 1 | 107 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 29, 2022 | clinicaltrials |
| NCT03301636 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma(NLG2107) | terminated | Phase 2 | 21 | NewLink Genetics CorporationINDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT00507325 | Sample Collection From Melanoma Patients | terminated | — | 131 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT03526185 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | terminated | Early Phase 1 | 6 | Yale UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01744171 | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | terminated | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03259425 | Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03332589 | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | terminated | Phase 1 | 4 | Spirita Oncology, LLCINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | terminated | Phase 2 | 8 | TC BiopharmINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | terminated | Phase 2 | 7 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01918930 | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 | terminated | Phase 1 | 6 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02054104 | Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | terminated | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | terminated | Phase 3 | 20 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 5 | Jan 19, 2022 | clinicaltrials |
| NCT02818023 | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | terminated | Phase 1 | 9 | Yana NajjarOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT00758797 | A Novel Treatment for Metastatic Melanoma | terminated | Phase 1 | 7 | Northwestern UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy | terminated | — | 98 | National Cancer Institute (NCI)NIH | 1 | Nov 10, 2021 | clinicaltrials |
| NCT02009384 | Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox | terminated | Phase 2 | 2 | University of LouisvilleOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT02355574 | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results(INTEGRATE) | terminated | — | 301 | Castle Biosciences IncorporatedINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02355587 | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes(EXPAND) | terminated | — | 72 | Castle Biosciences IncorporatedINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT00615160 | PTK/ZK in Disseminated Malignant Melanoma | terminated | Phase 1 / Phase 2 | 9 | Michael WeichenthalOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02375984 | A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas(TIL) | terminated | Phase 2 | 1 | Saint John's Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02974803 | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | terminated | Phase 2 | 6 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 241 | Dynavax Technologies CorporationINDUSTRY | 4 | Aug 3, 2021 | clinicaltrials |
| NCT02650492 | Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma | terminated | N/A | 2 | Clinical Laserthermia Systems ABINDUSTRY | 1 | Jul 7, 2021 | clinicaltrials |
| NCT03394937 | Safety of Intranodal ECI-006 in Melanoma Patients | terminated | Phase 1 | 21 | eTheRNA immunotherapiesINDUSTRY | 2 | Jun 21, 2021 | clinicaltrials |
| NCT02097732 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | terminated | Phase 2 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT04473027 | BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs(BLOOD) | terminated | — | 3 | University Hospital, GhentOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT03224208 | Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients(VECODUE) | terminated | Phase 2 | 9 | Fondazione Melanoma OnlusOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT03724968 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | terminated | Phase 2 | 2 | Elizabeth DavisOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT00961844 | Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma | terminated | Phase 1 / Phase 2 | 15 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03727087 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma | terminated | — | 348 | Exact Sciences CorporationINDUSTRY | 1 | Feb 10, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 21, 2022source: clinicaltrials